ГИПЕРАКТИВ ҚОВУҚНИ ДАВОЛАШНИНГ ЗАМОНАВИЙ УСУЛЛАРИ
Keywords:
Калит сўзлар: гиперактив сийдик пуфаги, антихолинергик даво, солифенацин, қарор қабул қилишнинг мультикритериал таҳлили, ФОРТА таснифи.Abstract
Аннотоация. Тақдим этилган адабиётларнинг шарҳ маълумотлари бўйича
ҳаддан ташқари фаол сийдик пуфаги (генератив қовуқни) касаллигининг
эпидемиологик, клиник ва даволашнинг замонавий ёндашувлари тўғрисида
маълумотлар келтирилган. Касалликни даволашда етакчи рол ўйнайдиган
антихолинергик препаратларни қўллашнинг фармакологик асослари
тасвирланган. Ушбу ишда М-ҳолиноблокатордан, хусусан, солифенациндан
фойдаланишнинг фармакологик ва клиник жиҳатлари кўриб чиқилади. Ушбу
препарат М3-холинергик рецепторларнинг рақобатбардош блокаторларига
тегишли. Ўтказилган тадқиқотлар солифенациннинг юқори клиник
самарадорлигини кўрсатди. Паст липофиллик ва юқори молекуляр оғирлик
туфайли препаратнинг гематоэнцефалк тўсиғига кириш қобилияти минималдир,
бу эса марказий асаб тизимидан ножўя таъсирларнинг паст частотасини
келтириб чиқаради. Солифенациннинг фармакокинетик ва фармакодинамик
хусусиятлари уни беморларнинг "заиф" гуруҳларига - қарияларга, марказий асаб
тизими касалликлари ва когнитив нуқсонлари бўлган беморларга буюриш
имконини беради.
ФОРТА тизимига кўра, солифенацин В тоифасига кирувчи антимускарин
воситадир. Солифенацинни турли клиник ҳолатларда қўллашнинг амалий
масалалари кўриб чиқилган.
References
Адабиётлар рўйхати:
Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of
overactive bladder and how are they managed? A population-based prevalence
study. BJU Int. 2001;87(9):760–766.
Nabi G., Cody J.D., Ellis G. et al. Anticholinergic drugs versus placebo for
overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 2006;4
CD003781.
Abrams P., Swift S. Solifenacin is effective for the treatment of OAB dry patients:
a pooled analysis. Eur. Urol. 2005;48(3):483–487.
Chapple C.R., Martinez-Garcia R., Selvaggi L. et al. A comparison of the efficacy
and tolerability of solifenacin succinate and extended release tolterodine at
treating overactive bladder syndrome: results of the STAR trial. Eur. Urol.
;48(3):464–470.
Cardozo L., Heßdörfer E., Milani R. et al. Solifenacin in the treatment of urgency
and other symptoms of overactive bladder: results from a randomized, double-
blind, placebo-controlled, rising-dose trial. Br. J Urol. Int. 2008;102(9):1120–
Sears C.L.G., Lewis C., Noel K. et al. Overactive bladder medication adherence
when medication is free to patients. J Urol. 2010;183(3):1077–1081.
D'Souza A.O., Smith M.J., Miller L.A. et al. Persistence, adherence, and switch
rates among extended-release and immediate-release overactive bladder
medications in a regional managed care plan. J Managed Care Pharmacy.
;14(3):291–301.
Haab F., Castro-Diaz D. Persistence with antimuscarinic therapy in patients with
overactive bladder. Int J Clin Pract. 2005;59(8):931–937.
Chapple C.R., Rosenberg M.T., Brenes F.J. Listening to the patient: a flexible
approach to the use of antimuscarinic agents in overactive bladder syndrome. Br
J Urol Int. 2009;104(7):960–967.
Wyndaele J.-J., Goldfischer E.R., Morrow J.D. et al. Effects of flexible-dose
fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-
label study. Int J Clin Pract. 2009;63(4):560–567.
Raxmanova L.K., Tursunbaev А.K. Pentalogy of athology of pregnancy in
mothers is a risk factor for the development of Alport syndrome in children. China
Petroleum Processing and Petrochemical Technology, Volume 23, Issue 2,
October 2023, 2021-2036.
Chu F., Smith N., Uchida T. Efficacy and Safety of Solifenacin Succinate 10 mg
Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-
Controlled, Parallel-Group Trial in Patients With Overactive Bladder. Curr Ther
Res Clin Exp. 2009; 70: 405–420.
Chancellor M.B., Zinner N., Whitmore K. et al. Efficacy of solifenacin in patients
previously treated with tolterodine extended release 4 mg: results of a 12-week,
multicenter, open-label, flexible-dose study. Clinical Therapeutics.
;30(10):1766–1781.
Zinner N., Kobashi K. C., Ebinger U. et al. Darifenacin treatment for overactive
bladder in patients who expressed dissatisfaction with prior extended-release
antimuscarinic therapy. Int J Clin Pract. 2008;62(11):1664–1674.
Wyndaele J.-J., Goldfischer E.R., Morrow J.D. et al. Patient-optimized doses of
fesoterodine improve bladder symptoms in an open-label, flexible-dose study. Br
J Urol. Int.2011;107(4):603–611.
Karram M.M., Toglia M.R., Serels S.R. et al. Treatment with solifenacin increases
warning time and improves symptoms of overactive bladder; results from
VENUS, a randomised double blind placebo-controlled trial. Urology
;73:14–18.
Garley A.D., Kaufman J.M., Sand P.K. et al. Symptom bother and healthrelated
quality of life outcomes following solifenacin treatment for overactive bladder:
the Vesicare open label trial. Clin. Ther. 2006;28:1935–1946.
Michel M.C., Wetterauer U., Vogel M. et al. Cardiovascular safety and overall
tolerability of solifenacin in routine clinical use: a 12 week open label
postmarketing surveillance study. Drug Saf. 2008;31:505–514.
